The concurrent use of highly active antiretroviral therapy (HAART) improves results of high-dose chemotherapy with autologous stem cell transplantation (SCT) for human immunodeficiency virus-1 (HIV)-associated lymphomas.
1
Recently, successful allogeneic SCT from HLA-matched sibling donors was reported in HIV-infected patients. [2] [3] [4] Here, we describe the first case of an HIV-infected patient with acute lymphoblastic leukemia (ALL) who underwent umbilical cord blood transplantation (CBT).
In July 1996, a 23-year-old Japanese woman presented with fever and genital herpes. She was confirmed as seropositive for HIV, probably transmitted from her boyfriend. In March 2001, a real-time quantitative polymerase chain reaction (PCR) analysis showed that the HIV-RNA level was elevated to 25 000 copies/ml (lower limit of detection, 50). The CD4 count decreased to 28/ml. Therefore, HAART consisting of 60 mg stavudine, 300 mg lamivudine, and 600 mg efavirenz was initiated. In July 2001, the HIV-RNA level decreased to 220 copies/ml, and the CD4 count increased to 129/ml. In May 2003, her complete blood count tests showed a white blood cell count (WBC) of 3990/ml with 29% lymphoblasts. Bone marrow (BM) examination showed hypercellularity with 96% lymphoblasts, which were positive for CD4, CD10, CD13, CD19, CD33, CD34, and HLA-DR. Cytogenetic analysis disclosed the presence of t(9;22)(q34;q11) in 12 of 20 metaphases. The p190 BCR-ABL transcript was shown by a reverse transcriptase (RT)-PCR analysis. She was diagnosed as Philadelphia chromosome-positive ALL. She achieved hematological complete remission after two courses of chemotherapy. She has been taking HAART during and after the chemotherapy and her HIV-RNA level continued to be below detectable levels. She was negative for hepatitis B virus surface antigen and anti-hepatitis C virus antibody, and positive for anti-cytomegalovirus antibody. As she had no HLA-matched related or unrelated BM donors, the patient underwent CBT from an unrelated donor with mismatches at two loci Bone
www.nature.com/bmt blood (CB) unit were 2.9 Â 10 7 /kg and 0.76 Â 10 5 /kg, respectively. The conditioning regimen included 12 Gy total body irradiation and 120 mg/kg cyclophosphamide. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate. The patient tolerated the procedure well with minimal regimen-related toxicity. Owing to possible myelosuppression, HAART was discontinued on day þ 28. On day þ 33, her WBC remained below 100/ml and all of the BM cells were shown to be derived from the recipient. At 40 days after the first CBT, second CBT was performed from an unrelated donor with a one-locus mismatch at HLA-DR. The numbers of total nucleated cells and CD34-positive cells in the CB unit were 2.1 Â 10 7 /kg and 0.46 Â 10 5 /kg, respectively. The conditioning regimen included 40 mg/m 2 fludarabine for 3 days. Cyclosporine was administered for GVHD prophylaxis. A neutrophil count consistently greater than 500/ml was achieved on day þ 27. Full donor chimerism of BM cells was shown on day þ 28. The HIV-RNA level increased to 3 Â 10 6 copies/ml on day þ 31. After the administration of HAART from day þ 38, the HIV-RNA levels returned to below detectable levels from day þ 195, and the CD4 count increased to above 300/ml from day þ 170. No bacterial or fungal infections were documented during the first and second CBT processes and cytomegalovirus reactivation was successfully treated with ganciclovir and foscarnet. Grade I acute GVHD occurred, but resolved without any additional immunosuppressants. No chronic GVHD was observed. An RT-PCR analysis showed continuous negative test results for the p190 BCR-ABL transcript until the last follow-up evaluation at 15 months post-CBT.
CBT for adults has been associated with a high rate of early transplantation-related mortality (TRM). 5, 6 However, our single-institution experience showed a 1-year TRM of 9% and 2-year disease-free survival of 74% in 68 adults after CBT. 7 Both CB donors and the patient in the present study were Japanese. The lesser genetic diversity in a single ethnic population in our studies might be associated with the favorable outcomes of CBT, such as the lower rates of severe acute GVHD. Although our results suggest that CBT is feasible for HIV-infected patients on HAART, the safety and efficacy should be further examined by prospective studies. 
